AstraZeneca To Replace Xilinx In Nasdaq-100
$AZN
$XLNX
Biotechnology: Pharmaceutical Preparations
Health Care
Semiconductors
Technology
AstraZeneca To Replace Xilinx In Nasdaq-100
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/13/2025 | Neutral → Buy | UBS | ||
| 2/12/2025 | Overweight | Morgan Stanley | ||
| 11/20/2024 | Sell → Neutral | UBS | ||
| 11/6/2024 | Sell → Hold | Deutsche Bank | ||
| 9/13/2024 | Hold → Sell | Deutsche Bank | ||
| 5/30/2024 | $97.00 | Buy | Goldman | |
| 4/16/2024 | Sell → Hold | Deutsche Bank | ||
| 2/8/2024 | Hold → Sell | Deutsche Bank |
IMFINZI reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca's IMFINZI® (durvalumab), administered perioperatively in combination with neoadjuvant chemotherapy, demonstrated improvements in event-free survival (EFS) and overall survival (OS) versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response (pCR) in muscle-invasive bladder cancer (MIBC). Patients were treated with four cycles of IMFINZI in combination with neoadjuvant chemotherapy before radical cystectomy (surgery
Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue 2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue 54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29
The first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant DATROWAY® (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy versus standard of care in patients with stage 1 adenocarcinoma non-small cell lung cancer (NSCLC) after complete surgical resection who are ctDNA-positive or have other high risk pathological features. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (NASDAQ:AZN). Standard treatment for stage 1 NSCLC is tumor resection, but up to 40%
6-K - ASTRAZENECA PLC (0000901832) (Filer)
EFFECT - ASTRAZENECA PLC (0000901832) (Filer)
6-K - ASTRAZENECA PLC (0000901832) (Filer)
Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue 2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue 54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum AstraZeneca: Revenue and EPS summary 9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance Revenue 1,498 49 50 559 48 50 - Collaboration Revenue 108 (66) (66) 59 (39) (40) Total Revenue 39,182 16 19 13,565 18 21 Reported EPS $3.57 11 21
ODD and RPDD granted by the FDA and ODD granted by the European Commission to UCART22 for the treatment of ALLODD granted by the FDA to CLLS52 (alemtuzumab) for ALL treatmentCash position of $273 million as of June 30, 20241; cash runway projection into 2026 NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024. "Over the past months, we have achieved a significant milestone with the granting of ODD designations by
UBS upgraded AstraZeneca from Neutral to Buy
Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight
UBS upgraded AstraZeneca from Sell to Neutral
4 - XILINX INC (0000743988) (Issuer)
4 - XILINX INC (0000743988) (Issuer)
4 - XILINX INC (0000743988) (Issuer)
SC 13G/A - XILINX INC (0000743988) (Subject)
SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)
SC 13G/A - XILINX INC (0000743988) (Subject)
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical
In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for